0000000000136725

AUTHOR

Luis Querol

showing 4 related works from this author

Clinical characteristics and outcomes of thymoma-associated myasthenia gravis

2021

[Background and purpose] Prognosis of myasthenia gravis (MG) in patients with thymoma is not well established. Moreover, it is not clear whether thymoma recurrence or unresectable lesions entail a worse prognosis of MG.

medicine.medical_specialtyThymomaThymomaEnfermedad del sistema nerviosoMiastenia gravischemical and pharmacologic phenomenaGastroenterology03 medical and health sciences0302 clinical medicineDisease severityRecurrenceInternal medicinehemic and lymphatic diseasesMyasthenia GravismedicineHumansIn patient030212 general & internal medicineneoplasmsNeurologíaMyasthenia gravisRetrospective Studiesbusiness.industryHazard ratioOdds ratioThymus Neoplasmsthymomamedicine.diseaseThymectomyPrognosisConfidence intervalMyasthenia gravisThymomEfectos fisiológicossurgical procedures operativeNeurologyMulticenter studySignos y síntomasNeurology (clinical)Neoplasm Recurrence LocalbusinessTimoma030217 neurology & neurosurgery
researchProduct

Clinical and therapeutic features of myasthenia gravis in adults based on age at onset

2020

[Objective] To describe the characteristics of patients with very-late-onset myasthenia gravis (MG).

AdultMalePediatricsmedicine.medical_specialtyThymomagenetic structuresCross-sectional studyInvestigación médicaEnfermedad del sistema nerviosoMEDLINEMiastenia gravisLate onsetDISEASECLASSIFICATIONArticleACETYLCHOLINE-RECEPTOR03 medical and health sciences0302 clinical medicineimmune system diseasesMyasthenia GravismedicineEnfermedades neuromuscularesHumansRITUXIMAB030212 general & internal medicineAge of OnsetAgedbusiness.industryAnálisis de datosMiddle Agedmedicine.diseaseMyasthenia gravisnervous system diseasesCross-Sectional StudiesTreatment OutcomeMulticenter studyANTIBODIESAUTOANTIBODIESFemaleObservational studyNeurology (clinical)Age of onsetbusiness030217 neurology & neurosurgeryMUSK
researchProduct

Multi-centre validation of a flow cytometry method to identify optimal responders to interferon-beta in multiple sclerosis.

2018

Background and objectives: Percentages of blood CD19 + CD5 + B cells and CD8 + perforin + T lymphocytes can predict response to Interferon (IFN)-beta treatment in relapsing-remitting multiple sclerosis (RRMS) patients. We aimed to standardize their detection in a multicenter study, prior to their implementation in clinical practice. Methods: Fourteen hospitals participated in the study. A reference centre was established for comparison studies. Peripheral blood cells of 105 untreated RRMS patients were studied. Every sample was analyzed in duplicate in the participating centre and in the reference one by flow cytometry. When needed, participating centres corrected fluorescence compensations…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyMultiple SclerosisIntraclass correlationConcordanceT cellClinical BiochemistryImmunologyBiochemistrySpearman's rank correlation coefficientMultiple sclerosis03 medical and health sciences0302 clinical medicineInternal medicineMedicineHumansMulticenter Studies as TopicFlow cytometryB cellbusiness.industryMultiple sclerosisBiochemistry (medical)General MedicineInterferon-betaMiddle Agedmedicine.diseaseFlow Cytometry030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisFemaleCD5businessCD8BiomarkersClinica chimica acta; international journal of clinical chemistry
researchProduct

The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis

2018

ObjectiveTo evaluate whether the clinical benefit and relapse rates in anti-muscle-specific kinase (MuSK) myasthenia gravis (MG) differ depending on the protocol of rituximab followed. MethodsThis retrospective multicentre study in patients with MuSK MG compared three rituximab protocols in terms of clinical status, relapse, changes in treatment, and adverse side effects. The primary effectiveness endpoint was clinical relapse requiring a further infusion of rituximab. Survival curves were estimated using Kaplan-Meier methods and survival analyses were undertaken using Cox proportional-hazards models. ResultsTwenty-five patients were included: 11 treated with protocol 4 + 2 (375 mg/m(2)/4 w…

0301 basic medicinemedicine.medical_specialtyTime to relapseRelapse rateGastroenterologyAssaigs clínics de medicaments03 medical and health sciencesMalalties del sistema nerviós0302 clinical medicineimmune system diseasesInternal medicineMedicineIn patientRelapse riskAdverse effectSurvival analysisbusiness.industryGeneral NeuroscienceNervous system DiseasesDrug testingmedicine.diseaseMyasthenia gravis030104 developmental biologyRituximabNeurology (clinical)business030217 neurology & neurosurgerymedicine.drug
researchProduct